Low Serum Ferritin Level Rules Out Advanced Liver Disease in Hemochromatosis. Ann Intern Med. 2003;138:I-30. doi: 10.7326/0003-4819-138-8-200304150-00003
Download citation file:
Published: Ann Intern Med. 2003;138(8):I-30.
Hemochromatosis is an inherited disorder. It results from an abnormal gene that causes the body to absorb too much iron from food. People with the disorder have high levels of serum ferritin, a measure of body iron stores. The excess iron gradually builds up in many organs, including the liver. As the disease progresses, damage to the liver can lead to permanent scarring (fibrosis and cirrhosis) and liver cancer. Treatment involves avoiding alcohol (because it increases iron absorption and may cause liver damage) and removing excess iron by drawing off pints of blood. Liver cancer occurs mostly in patients who already have advanced liver disease (bridging fibrosis or cirrhosis). Some doctors regularly monitor these patients with ultrasound tests to detect liver cancer. In the past, the diagnosis of advanced fibrosis or cirrhosis has required a liver biopsy. Doctors and patients would appreciate less invasive tests to help identify the patients with advanced liver disease who might need regular monitoring for liver cancer.
To see whether the serum ferritin level can help identify patients with hemochromatosis who do or do not have advanced liver disease.
182 adults with hemochromatosis.
The researchers reviewed records from six referral centers to identify patients with hemochromatosis. They picked only patients who had no other causes for liver disease and who had liver biopsies and serum ferritin blood tests at the time of diagnosis. The researchers checked the biopsy specimens for findings of advanced liver disease (bridging fibrosis or cirrhosis). They then compared serum ferritin levels in patients with and without advanced liver disease. (Normal serum ferritin levels are 10 to 200 µg/L. Patients with hemochromatosis have levels ranging from 200 to 6000 µg/L.)
Forty patients had advanced liver disease. Most patients with advanced liver disease had serum ferritin levels greater than 1500 µg/L. Only one patient had a serum ferritin level less than 1000 µg/L. Sixty-five percent of the patients without advanced liver disease had serum ferritin levels less than 1000 µg/L.
The study was based on records of patients who had been seen at referral centers and who had multiple tests for liver disease. These patients may have had severe disease and may not be typical of most patients with hemochromatosis.
Patients with hemochromatosis and serum ferritin levels less than 1000 µg/L are unlikely to have advanced liver disease. Liver biopsy to detect advanced liver disease in such patients is probably not needed.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Gastroenterology/Hepatology, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only